Remove Food Remove Pharmaceutical manufacturing Remove Prescription
article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

The US Food and Drug Administration (FDA) believes the adulteration of heparin was an economically motivated act—a clear breach of the US pharmaceutical supply chain. The answer lies in both an outdated way we develop prescription drugs and the continued quest for the next big blockbuster. In other words, money over safety.

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. Actavis, 570 U.S. 136 (2013), [link] opinions/12pdf/12-416_m5n0.pdf.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Diversity and inclusion in oncology clinical trials

Clarify Health

Food and Drug Administration (FDA) released guidance entitled, Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry. To advance equity in clinical research, the U.S.

article thumbnail

New IFPMA and EFPIA guidance on use of social media by the pharmaceutical industry

pharmaphorum

Jackie Mulryne, Partner, is a member of the Life Sciences practice group, and provides regulatory, policy, and compliance advice to clients in the pharmaceutical, medical technology, cosmetics, and foods sectors.

Media 98